← Back to Clinical Trials
Recruiting NCT06640101

NCT06640101 Effects of Inspiratory Muscle Training on Stroke Rehabilitation Outcomes

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06640101
Status Recruiting
Phase
Sponsor Hong Kong Metropolitan University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 84 participants
Start Date 2025-02-21
Primary Completion 2025-10-15

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
sham IMTIMT-stable group (sitting on a stable surface)IMT-unstable group (sitting on an unstable surface)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 84 participants in total. It began in 2025-02-21 with a primary completion date of 2025-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is designed to explore the effects of a 4-week protocol of inspiratory muscle training (IMT) at 50% maximum inspiratory pressure (MIP) on respiratory function, diaphragm thickness, balance control, exercise capacity, and quality of life in people after stroke. To ascertain the effect of IMT on the relationship between diaphragm muscle contraction and activation of other trunk muscles, this study also explores whether any effect of the 4-week IMT protocol on balance control is associated with changes in the anticipatory posture adjustments (APAs) time - the onset time of postural muscles during a required task (e.g., the rapid shoulder flexion test).

Eligibility Criteria

Inclusion Criteria: * Age ≥ 40 years and \< 80 years; * breathing spontaneously; * clinically diagnosed with ischemic and/or haemorrhagic stroke; * duration of stroke from onset falls within 1 month to 12 months after diagnosis; * no thoracic or abdominal surgery within the last 6 months; * able to understand and follow verbal instructions; * no facial palsy, or mild facial palsy without limitation of labial occlusion; * able to maintain a resting sitting posture without feet support for at least 30 seconds; * no cognitive impairment (Montreal Cognitive Assessment (MoCA) score ≥ 26); * able to independently walk at least 10 meters with or without an assistive device. Exclusion Criteria: * acute myocardial infarction or acute heart failure; * acute pain in any part of the body; * with respiratory illness or positive clinical signs of impaired respiratory function (such as shortness of breath, hypoxemia, chronic cough and sputum retention); * with chronic cardiovascular dysfunction; * Trunk Impairment Scale (TIS) score ≥ 20. * patient with a nasal feeding tube, tracheal tube and/or any condition that prevents the measurement or the implementation of the study procedure.

Contact & Investigator

Central Contact

Fang LIU

✉ s1350035@live.hkmu.edu.hk

📞 +86 13603049475

Frequently Asked Questions

Who can join the NCT06640101 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06640101 currently recruiting?

Yes, NCT06640101 is actively recruiting participants. Contact the research team at s1350035@live.hkmu.edu.hk for enrollment information.

Where is the NCT06640101 trial being conducted?

This trial is being conducted at Shenzhen, China.

Who is sponsoring the NCT06640101 clinical trial?

NCT06640101 is sponsored by Hong Kong Metropolitan University. The trial plans to enroll 84 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology